Shandong Sanyuan Biotechnology Co., Ltd. (301206.SZ) manufactures and markets functional sugar alcohols and compound sweeteners, primarily erythritol, allulose, high-purity steviol glycosides such as rebaudioside M, and blended products including momordica grosvenori compound sugar, stevia compound sugar, and sucralose compound sugar; these are applied in table sugar, flavored sugar, beverages, candy, chocolate, baked goods, health foods, medical supplies, cosmetics, and chemical products. Founded in 2007 and headquartered in Binzhou, Shandong Province, China, the company operates a biological fermentation-based production process with an annual erythritol capacity of 5,000 tons and exports to Europe, the United States, East Asia, Southeast Asia, Australia, New Zealand, and Africa. In 2024, the company completed a CNY 100 million share repurchase program, repurchasing 2.3257 million shares by July 2025, and announced cash dividends for the third quarter of 2025 at an upcoming EGM; its allulose production license remains in process, supporting expansion into rare monosaccharides with properties akin to sucrose but nearly zero calories.